AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Double-stranded RNA-specific adenosine deaminase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P55265

UPID:

DSRAD_HUMAN

Alternative names:

136 kDa double-stranded RNA-binding protein; Interferon-inducible protein 4; K88DSRBP

Alternative UPACC:

P55265; B1AQQ9; B1AQR0; D3DV76; O15223; O43859; O43860; Q9BYM3; Q9BYM4

Background:

The Double-stranded RNA-specific adenosine deaminase, also known as Interferon-inducible protein 4, plays a crucial role in A-to-I RNA editing. This process involves the hydrolytic deamination of adenosine to inosine in double-stranded RNA, impacting gene expression and function through various mechanisms such as mRNA translation, pre-mRNA splicing, and RNA stability. Its editing capabilities extend to both viral and cellular RNAs, influencing the functional activities of proteins and the genetic stability of RNA virus genomes.

Therapeutic significance:

Linked to diseases like Dyschromatosis symmetrica hereditaria and Aicardi-Goutieres syndrome 6, this protein's unique function in RNA editing and virus replication modulation highlights its potential as a target for therapeutic intervention. Understanding the role of Double-stranded RNA-specific adenosine deaminase could open doors to potential therapeutic strategies, especially in genetic and viral diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.